anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a killer toxin-containing powder, having excellent preservation quality, stable to temperature, etc., and useful for preventing organic contamination in the brewing industry, etc., by concentrating the powdering a solution containing a killer toxin containing a specific compound, e.g. polysaccharides, etc., present therein. CONSTITUTION:A killer toxin-containing powder obtained by blending and powdering cultivation filtrate, of a killer yeast belonging to the genus Saccharomyces, Candida, etc., aqueous solution of a killer toxin, solution containing K1-K11 type killer toxin or new type killer toxin produced by Candida vines SW55, in the presence of one or two more selected from polysaccharides, e.g. cyclodextrin, etc., saccharides, e.g. glucose, etc., sugaralcohols, e.g. sorbitol, etc., and ammonium sulfate. The above-mentioned powder is capable of exhibiting germicidal effects or preventing effects on microbial contamination when added to to unrefined SAKE (Japanese rice wine), fruits juice or product SAKE and fermentation stopping effects when added to unrefined SAKE at the completion of fermentation thereof.
The method for preventing the pyo-inflammatory complications after Cesarean section comprises the use of antibiotics intraoperatively and in the first two postoperative days. The risk for the postoperative complications is assessed using the special scale. The sum of points equaling 4 suggests the low risk, the sum of points within 5-10 range suggests the moderate risk, and the sum of points exceeding 10 is indicative of high risk. When the risk is low, Ceftriaxon is administered dropwise intraoperatively, Meratin (Ornidasol) is applied to the peritoneal cavity; postoperatively Ceftriaxon is administered i/v and Meratin i/v dropwise on the first day and Ceftriaxon is administered on the second day. When the risk is moderate, Ceftriaxon 1.0 is administered i/v intraoperatively, Meratin is applied to the peritoneal cavity and i/v dropwise; postoperatively Ceftriaxon is administered i/v on the first day, and in 24 hours Ceftriaxon i/v and Meratin i/v are used; on the second day Ceftriaxon i/m is injected every 12 hours; Ceftriaxon i/m is injected also on the third day. When the risk is high, Tebris (Gatifloxin) is used i/v dropwise intraoperatively and Meratin is applied to the peritoneal cavity; on the first postoperative day Tebris is administered i/v dropwise, and in 24 hours Tebris and Meratin are administered i/v dropwise; on the second day Tebris is administered i/v dropwise, and on Days 3-5 Tebris is taken per os.
Processes for reducing the amount of impurities, especially α,β-unsaturated ketones (ABUK), in materials containing morphine. Novel compounds, namely low ABUK morphine sulfate methanolic solvate, and a novel crystal form are also described. The method for making morphine sulfate methanolic solvate comprises mixing a morphine free base composition with methanol to form a solution and adding a liquid comprising sulfuric acid to the solution to form a morphine sulfate methanolic solvate precipitate. A method of making a morphine sulfate compound comprises drying the morphine sulfate methanolic solvate in the presence of water vapor, such that methanol molecules are removed and replaced with water vapor molecules. A composition for treating pain comprises the morphine sulfate compound and at least one pharmaceutically acceptable excipient. A method for treating pain comprises administering to a patient in need thereof the composition comprising the morphine sulfate compound and at least one pharmaceutically acceptable excipient.
Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
The invention relates to the field of vaccinology and in particular relates to vibrio harveyi outer membrane protein and an application thereof. The outer membrane protein is shown as amino acid sequences in sequence tables SEQ ID No. 1 and No. 2. Specifically, vibrio harveyi T4 serves as a template; polymerase chain reaction (PCR) amplification is respectively performed by using 173F/173R and 214F/214R as primers respectively; the obtained PCR products are connected with a vector pEASY-E2 respectively; the obtained connecting liquid is transformed into escherichia coli DH5alpha; the screening plasmids are pOMP173 and pOMP214; the plasmids are used for transforming escherichia coli BL21(DE3) respectively and expressing recombinant protein containing OMP173 and OMP214 sequences as shown in SEQ ID No. 1 and No. 2. The immunoprotection efficiency of the OMP173 or OMP214 outer membrane protein serving as a vaccine on the vibrio harveyi is more than 70%.
Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.
Although desert dust promotes morbidity and mortality, it is exempt from regulations. Its health effects have been related to its inflammatory properties, which can vary between source regions. It remains unclear which constituents cause this variability. Moreover, whether long-range transported desert dust potentiates the hazardousness of local particulate matter (PM) is still unresolved. We aimed to assess the influence of long-range transported desert dust on the inflammatory potency of PM2.5 and PM10 collected in Cape Verde and to examine associated constituents. During a reference period and two Saharan dust events, 63 PM2.5 and PM10 samples were collected at four sampling stations. The content of water-soluble ions, elements, and organic and elemental carbon was measured in all samples and endotoxins in PM10 samples. The PM-induced release of inflammatory cytokines from differentiated THP-1 macrophages was evaluated. The association of interleukin (IL)-1β release with PM composition was assessed using principal component (PC) regressions. PM2.5 from both dust events and PM10 from one event caused higher IL-1β release than PM from the reference period. PC regressions indicated an inverse relation of IL-1β release with sea spray ions in both size fractions and organic and elemental carbon in PM2.5. The PC with the higher regression coefficient suggested that iron and manganese may contribute to PM2.5-induced IL-1β release. Only during the reference period, endotoxin content strongly differed between sampling stations and correlated with inflammatory potency. Our results demonstrate that long-range transported desert dust amplifies the hazardousness of local air pollution and suggest that, in PM2.5, iron and manganese may be important. Our data indicate that endotoxins are contained in local and long-range transported PM10 but only explain the variability in inflammatory potency of local PM10. The increasing inflammatory potency of respirable and inhalable PM from desert dust events warrants regulatory measures and risk mitigation strategies.
Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
We report the first evidence that the gist mechanism of fuzzy-trace theory and the associative mechanism of activation monitoring theory operate in parallel, in the recall version of the Deese/Roediger/McDermott illusion. In three experiments, we implemented a new methodology that allows their respective empirical indexes, gist strength (GS) and backward associative strength (BAS), to each be manipulated while the other is held constant. In Experiment 1, increasing GS increased false recall of missing words, but increasing BAS did not. In Experiments 2 and 3, however, increasing GS and increasing BAS both increased recall of missing words, and those effects were independent and additive. In all three experiments, GS and BAS affected true recall of list words in qualitatively different ways: (a) Increasing GS always improved true recall, regardless of whether BAS was high or low, but (b) increasing BAS impaired true recall when GS was high and improved true recall when GS was low. To pinpoint the retrieval loci of the two variables' effects, we analyzed the data of all experiments with the dual-retrieval model. Those analyses showed that the variables' respective effects were due to different retrieval processes. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
At least one example embodiment relates to a computer-implemented method for determining an imaging parameter value for the control of a medical technology device during a capture of a first image dataset. In this context, the first image dataset is provided to be transferred from the medical technology device to a remotely arranged device. The method comprises at least one of receiving or determining a transfer parameter value. In this context, the transfer parameter value comprises an information item concerning which image information is relevant for the first image dataset which is to be transferred. The method further comprises determining the imaging parameter value based on the transfer parameter value. The method further comprises providing the imaging parameter value.
Approximately 100 participants will be included and cluster randomized by nursing home (n= 3) to either 12 months of nutritional and physical intervention or 12 months of usual care (control). The Nutritional and Physical Intervention Group will receive nutritional and physical interventions collaboratively defined by residents, relatives, care staff, and nursing home management during the PDSA workshops.
This study is comprised of two phases: screening and treatment. The screening period is 24 hours, followed by the treatment phase of 15 ± 3 days. During the treatment phase, subjects will be randomized to either test, reference of placebo treatments (3:3:1) in a double-blind manner in an outpatient setting. Once eligibility is confirmed, randomization will occur at visit 2 (baseline, Day 1) i.e. initiation of treatment phase. The treatment phase will be 15 ± 3 days in duration wherein subject will receive treatment with investigational product (either test, reference or placebo) on Day 1 or baseline (visit 2). Efficacy will be evaluated at Day 15. Safety and tolerability will be evaluated based upon AEs and patient self-assessments and self-assessments collected during follow-up visits.
Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after \~7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until \~7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
The SAGE arm is a garden-based curriculum that emphasizes outdoor learning opportunities such as active games, songs, and garden-activities. About half of the original 40 sites (roughly evenly divided by CHILD and CHILD+) will receive this in year one, and the remaining sites will receive this condition in year two.
Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg\*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
The present invention relates to a plaster medical composition with multiple purposes for treating affection pain due to dampness. The present invention is characterized in that the composition comprises the following active components by weight percentage: raw materials of tubers Chinese herbal medicines: 100 to 160 of clematis root, 100 to 160 of boston ivy, 30 to 70 of sargentgloryvine stem, 30 to 70 of curare, 30 to 70 of common monkshood mother root, 30 to 70 of kusnezoff monkshood root, 70 to 130 of common floweringquince fruit, 20 to 60 of angelica, 15 to 45 of rhizoma et radix notopterygii, 15 to 45 of angelicae pubescentis, 15 to 45 of twotooth achyranthes root, 15 to 45 of rhizoma, 15 to 45 of gentiana macrophylla, 15 to 45 of common prism rhizome and 15 to 45 of zedoary; medical raw materials in the classes of insects and animals: 30 to 80 of scorpion and 35 to 90 of long-nosed pit viper; medical raw materials of decocted later class: 35 to 85 of olibanum, 35 to 85 of myrrh, 35 to 85 of dragon blood, 35 to 85 of rhizoma corydalis, 5 to 15 of moschus and a proper amount of dondain. The present invention uses true benne oil and dondain as base materials and ensures the medical durability. Compared with the prior art, the present invention has the functions of dredging meridian channels, expelling wind, clearing away cold, promoting blood circulation for removing blood stasis, removing tumidness, relieving pain, etc., and has conspicuous curative effect. Through clinical experiment, the present invention is used for aching pain, gall and affection pain due to rheumatism, is used for treating arthritis, periarthritis of shoulders, and hyperostosis, and is also used for medium-term and latter gall due to bite of a venomous snake, and the therapeutic effect reaches more than 90% after the patients who have limitation of activity use the medicine. The present invention has the characteristics of multiple purposes, wide application range, simple application.
The invention discloses a spray for treating scalds and burns and a preparation method thereof. The preparation method comprises the following steps: 1) selecting and cleaning; 2) soaking; 3) and (5) filtering and subpackaging. The spray has the effects of relieving swelling and pain, promoting blood circulation and nourishing blood, astringing dampness and healing sore, promoting granulation and healing wound, resisting bacteria and diminishing inflammation, relieving pain, protecting wound surfaces from infection and promoting wound healing. The external medicine fully stimulates the regeneration capability of human cells to promote the muscle tissue to grow again quickly, thereby achieving the treatment effect of short-term recovery. The application method is simple, and the medicine can be applied to the wound surface of a patient in a short time without treatment. The external medicine has more direct effect, simple dressing change and less pain, is beneficial to observing the change of the wound surface, and the medicine can keep the wound surface moist without leaving scars after healing, hormone and toxic and side effects on the medicine film formed on the wound surface. Can be used for treating burn, scald, ultraviolet radiation injury, and electric injury due to toxic heat.
This will be a single arm observational study to include 100 subjects. After a clinical decision is made to implement a single drug substitution to ATV +/- RTV, there will be an initial screening visit, at which time the study will be presented to the patient and informed consent for participation will be obtained. A number of evaluations (including blood tests) will be completed to definitively assess a subject's eligibility to participate in this protocol. The patients will continue on their current therapy and will return within the next 14 days for an enrollment visit to review the blood test results and definitively confirm study eligibility. In particular, we will ascertain the continued presence of the side effect/toxicity motivating consideration of a change in therapy. This being down, the quality of life questionnaires (MOS-HIV and ASDM) will be administered for the first time. Once again, the patient will continue on their current HAART and return within the next 14 days for a baseline visit at which time the quality of life questionnaires (MOS-HIV and ASDM) will be administered once again, the results being averaged with those obtained at the time of the enrollment visit, this serving as a more rigorous evaluation of the patient's current status. The patient could be withdrawn from the study if the side effect/toxicity motivating consideration of a change in therapy is no longer present. At this baseline visit, all patients will switch the PI or NNRTI component of their regimen to ATV (+/- RTV). The decision to use boosted or unboosted ATV in this protocol will be left to the discretion of the treating physician. All patients will be receiving ATV (+/- RTV) with food. The dose of the unboosted ATV will be 300 mg (2 capsules, 150mg each) plus RTV (1 capsule, 100 mg). The patients will then be seen in follow up at weeks 4, 12, 24, 32, and 48 after the baseline visit. They will continue on their new therapy (including ATV +/- RTV) for this entire period of observation. Changes in the NRTI backbone will be permitted without constituting a study endpoint, while changes in the ATV +/- RTV that may be required for reasons of efficacy or toxicity will constitute such an endpoint, leading to a patient's withdrawal from the study. At each study visit, the quality of life questionnaires (MOS-HIV and ASDM) will be administered. The results will be compared to the mean results obtained at the enrollment and baseline visits, with each individual participant serving as his/her own control. Measures of adherence to HAART, CD4 cell counts and HIV plasma viral load will also be obtained at each study visit, and will constitute secondary study endpoints.
PURPOSE:To obtain an active oxygen eliminator, containing an ethylenediamine based chelate compound as an active ingredient and capable of eliminating active oxygen which is considered as a noxious substance. CONSTITUTION:An active oxygen eliminator containing at least one of com pound expressed by formula I (R<1>-R<4> are lower alkoxycarbonyl,carbamoyl or pyridyl), formula II (Py is pyridyl) and formula III as an active ingredient. The active oxygen, especially hydroxy radicals are causative substances exhibiting various toxicities in living bodies. This eliminator is effective in treating chronic rheumatism, collagen disease, chronic dermatopathy, arterioscle rosis, drug toxicosis, radiation, ultraviolet ray damage, etc. This active oxygen eliminator is preferably prepared by, e.g. dissolving the above-mentioned com pound in a vegetable oil (e.g. soybean oil), forming the resultant solution, together with soybean phospholipid or egg yolk phospholipid into an oil-in-water type microemulsion and providing a fatty emulsion containing the compound expressed by the formula in lipid microspheres.
Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in . Table 4

In , the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added. Table 4

The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when topiramate was given alone.

In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy (see ). PRECAUTIONS, Hyperammonemia and Encephalopathy Associated with Concomitant Valproic Acid Use
Dosage of prednisolone oral solution should be individualized according to the severity of the disease and the response of the patient. For infants and children, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.

Hormone therapy is an adjunct to and not a replacement for conventional therapy.

Dosage should be decreased or discontinued gradually when the drug has been administered for more than a few days.

The severity, prognosis, expected duration of the disease, and the reaction of the patient to medication are primary factors in determining dosage.

If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued.

Blood pressure, body weight, routine laboratory studies, including two-hour postprandial blood glucose and serum potassium, and a chest X-ray should be obtained at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with known or suspected peptic ulcer disease.

The initial dosage of prednisolone oral solution may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisolone oral solution should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. 

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of prednisolone oral solution for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.